COSMIC-312

About this trial

This Phase 3 study evaluates the safety and efficacy of cabozantinib in combination with atezolizumab versus the standard of care sorafenib in adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy.
A single-agent cabozantinib arm will be enrolled in which subjects receive single agent cabozantinib in order to determine its contribution to the overall safety and efficacy of the combination with atezolizumab.

Patient Profile

Adults with advanced hepatocellular carcinoma (HCC) who have not received previous systemic anticancer therapy

Where’s this trial being run?

St James’s Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.


Summary Data

Name: COSMIC-312
Number: 20-05
Full Title:

Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced hepatocellular carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy

Principal Investigator: Prof Maeve Lowery (St James's Hospital)
Type: Industry Sponsored
Sponsor:

Exelixis

Recruitment Started: Global:
Ireland: June 2020
Global Recruitment Target: 740
Ireland Recruitment Target: 5